Seattle Genetics CEO on Q1 earnings, Padcev bladder cancer drug

132 Views
Published
Seattle Genetics CEO Clay Siegall discussed early reception of Padcev, an antibody-drug conjugate for bladder cancer that received FDA approval in December.
Category
Crypto Trading
Tags
Be the first to comment